Carotid artery intima-media thickness in highly treated HIV-1 patients

Infezioni in Medicina

Volumn 16, Issue 1, 2008, Pages 15-20

  Leone, Sebastiano ^a   Amitrano, Maria ^a   D'Avanzo, Antonio ^a   Acone, Nicola ^a   Ciglio, Sergio ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

Cardiovascular diseases; Carotid artery intima media thickness; Colour doppler ultrasonography; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTERIAL WALL THICKNESS; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAROTID ARTERY; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; DISEASE DURATION; ECHOGRAPHY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; TREATMENT DURATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAROTID ARTERIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; TUNICA INTIMA; TUNICA MEDIA;

EID: 42049115055     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Mooser V. Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease? AIDS 17, 65-69, 2003.
2. Barbaro G., Klatt E.C. HIV Infection and the cardiovascular system. AIDS Rev. 4, 93-103, 2002.
3. Pignoli P., Tremoli E., Poli A., Oreste P., Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74, 1399-406, 1986.
4. d'Arminio Monforte A., Sabin C.A., Phillips A., et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch. Intern. Med. 165, 416-23, 2005.
5. Bozette S.A., Ake C.F., Tam H.K., Chang S.W., Louis T.A. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J. Med. 348, 702-710, 2003.
6. Friis-Moller N., Weber R., Reiss P., et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 17, 1179-1193, 2003.
7. Mary-Krause M., Cotte L., Simon A., Partisani M., Costagliola D. and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17, 2479-2486, 2003.
8. The Data Collection on Adverse Events of Anti-HIV Drugs: (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349, 1993-2003, 2003.
9. Holmberg S.D., Moorman A.C., Williamson J.M., et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360, 1747-1748, 2002.
10. Crouse J.R. Predictive value of carotid 2-dimensional ultrasound. Am. J. Cardiol. 88, 27-30, 2001.
11. Salonen J.T., Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 87, 56-65, 1983.
12. Grobbee D.E., Bots M.L. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J. Intern. Med. 236, 567-573, 1994.
13. Kanters S.D., Algra A., van Leeuwen M.S., Banga J.D. Reproducibility of in vivo carotid intima-media thickness measurements. A review. Stroke 28, 665-671, 1997.
14. Simon A., Megnien J.L., Levenson J. Coronary risk estimation and treatment of hypercholesterolemia. Circulation 96, 2449-2452, 1997.
15. Hazenberg M.D., Stuart J.W., Otto S.A., et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 95, 249-255, 2000.
16. Liu Z., Cumberland W.G., Hultin L.E., Kaplan A.H., Detels R., Giorgi J.V. CD8 T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 18, 332-340, 1998.
17. Hellerstein M., Hanley M.B., Cesar D., et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat. Med. 5, 83-89, 1999.
18. Lederman M.M., Kalish L.A., Asmuth D., et al. "Modeling" relationships among HIV-1 replication, immune activation and CD4+ -cell losses using adjusted correlative analyses. AIDS 14, 951-958, 2000.
19. Danesh J., Whincup P., Walker M., et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 321, 199-204, 2000.
20. Libby P. Inflammation in atherosclerosis. Nature 420, 868-874, 2002.
21. Maggi P., Lillo A., Perilli F., Maserati R., Chirianni A. Color-doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS 18, 1023-1028, 2004.
22. Seminari E., Pan A., Voltini G., et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 162, 433-438, 2002.
23. Chironi G., Escaut L., Gariepy J., et al. Carotid intima-media thickness in heavily pretreated HIV-infected patients. J. Acquir. Immune. Defic. Syndr. 32, 490-493, 2003.
24. Mercie P., Thiébaut R., Lavignolle V., et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann. Med. 34, 55-63, 2002.
25. Currier J.S., Kendall M.A., Zackin R., et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 19, 927-933, 2005.
26. Currier J.S., Kendall M.A., Henry K., et al. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 21, 1137-1145, 2007.